Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions 
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown 
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025 
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift 
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
PLANO, Texas, Feb. 06, 2017 -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today that Scott Drees, Chief Executive Officer, and Walter Berger, Chief Operating Officer & Chief Financial Officer, are scheduled to conduct a fireside chat presentation at the Leerink Partners 6th Annual Global Healthcare Conference in New York, NY. Management will also be available for one-on-one meetings at the conference.
| Event: | Leerink 6th Annual Global Healthcare Conference |
| Format: | Fireside Chat and One-on-One Meetings |
| Date: | Thursday, February 16, 2017 |
| Time: | 11:00 am ET |
A webcast of the Company’s fireside chat will be available by visiting the investor relations section of Nuvectra’s website at www.nuvectramed.com. A webcast replay of the chat will be available for 90 days.
About Nuvectra Corporation
Nuvectra™ is a neurostimulation company committed to helping physicians improve the lives of people with chronic neurological conditions. The Algovita® Spinal Cord Stimulation (SCS) System is our first commercial offering and is CE marked and FDA approved for the treatment of chronic pain of the trunk and/or limbs. Our innovative technology platform also has capabilities under development to support other neurological indications such as sacral nerve stimulation (SNS), and deep brain stimulation (DBS). In addition, our NeuroNexus subsidiary designs, manufactures and markets leading-edge neural-interface technologies for the neuroscience clinical research market. Visit the Nuvectra website at www.nuvectramed.com.
Company Contacts: Nuvectra Corporation Walter Berger, Chief Financial Officer (214) 474-3102 [email protected] Jennifer Armstrong, Media Relations (214) 474-3110 [email protected] Investor Contacts: The Ruth Group Nick Laudico (646) 536-7030 [email protected] Zack Kubow (646) 536-7020 [email protected]
